Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
SKRR to Commence Uranium Drill Program to Test Conductors at Clearwater West (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Immunitybio Inc IBRX

Healthcare Biotechnology
Immunitybio, Inc. is a vertically integrated, clinical-stage biotechnology company developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Using its proprietary platforms that amplify both the innate and adaptive branches of the immune system, its advances therapies and vaccines to defeat urologic and other cancers, as well as... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:IBRX)

ImmunityBio Announces Insurance Coverage of ANKTIVA® Across Multiple States with First Commercial Doses Administered Just Weeks After FDA Approval-Opening New Era for Immunotherapy Beyond Checkpoint Inhibitors

Business Wire 5 days ago

ImmunityBio Announces 2024 Annual Meeting of Stockholders with Company Update

Business Wire June 7, 2024

Connecting the Dots of ANKTIVA's Triangle Offense: A Deep Dive with Dr. Patrick Soon-Shiong and Dr. Ashish Kamat in a Three-Part UroToday Podcast

Business Wire May 17, 2024

Kuehn Law Encourages Investors of ImmunityBio, Inc. to Contact Law Firm

Newsfile May 16, 2024

ImmunityBio Completes GMP Drug Substance Manufacturing Sufficient for 170,000 Doses of ANKTIVA®

Business Wire May 7, 2024

ImmunityBio, Serum Institute of India Agree on an Exclusive Arrangement for Global Supply of Bacillus Calmette-Guerin (BCG) Across All Cancer Types

Business Wire May 2, 2024

ImmunityBio Executive Chairman Dr. Patrick Soon-Shiong to Discuss ANKTIVA® Approval in Fireside Chat at the Annual Conference of the American Urological Association

Business Wire April 30, 2024

ImmunityBio Announces Positive Overall Survival Results of Anktiva Combined With Checkpoint Inhibitors in Non-Small Cell Lung Cancer; Meeting Scheduled with FDA to Discuss Registration Path for ANKTIVA in Lung Cancer

Business Wire April 25, 2024

ImmunityBio Announces FDA Approval of ANKTIVA®, First-in-Class IL-15 Receptor Agonist for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer

Business Wire April 22, 2024
View More News ››

Opinion & Analysis (NDAQ:IBRX)

NantKwest Shares Jump More than 50% Following JP Morgan Healthcare Conference Presentation

Streetwise Reports January 17, 2020

CAR T-cell therapeutics: Alan Leong of BioWatch looks beyond the buzz for solid early-stage plays

Gail Dutton September 10, 2015
View More Opinion ››

Bullboard Posts (NDAQ:IBRX)

Why ImmunityBio Stock Is Trading Higher Thursday | Benzinga

NEWS: $IBRX Why ImmunityBio Stock Is Trading Higher Thursday | BenzingaImmunityBio, Inc. (NASDAQ:IBRX) shares are moving higher Thursday...
whytestocks - 5 days ago

ImmunityBio Announces Positive Overall Survival Results of A

News; $IBRX ImmunityBio Announces Positive Overall Survival Results of Anktiva Combined With Checkpoint Inhibitors in Non-Small Cell...
whytestocks - April 25, 2024

South Africa to make Immunities Vac.

ImmunityBio's COVID-19 Vaccine Will Be Manufactured In South Africa: Bloomberg (yahoo.com)
tturner617 - March 19, 2021

Feb 5 21.. Pill Now being tested

In S. Africa....  Covid vaccine pill enters clinical trials - Research Professional News
tturner617 - February 7, 2021

doubled investment in 3 weeks

Id say NK has considerable upside yet. They are on the warp 14 list for covid 19 vaccine development, their serum base has already been...
Covey1000 - June 3, 2020

*Crickets*

Is it over already? Has it just begun? What say you....
happerdan - May 27, 2020
View more Bullboard ››

Mullen Group Ltd.

Mullen Group Ltd.

Mullen Group is one of North America's largest logistics providers with a network of independently operated businesses ...
View More »